Ownership and insider activity for Cingulate Inc. (CING): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
Price
| Price | $5.09 |
| Market Cap | $69M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-16 | Schaffer Shane J. | A-Award | 197,650 | $876K |
| 2026-07-16 | Schaffer Shane J. | A-Award | 97,350 | $431K |
| 2026-07-16 | Downey Bryan Wade | A-Award | 67,000 | $297K |
| 2026-07-16 | Downey Bryan Wade | A-Award | 33,000 | $146K |
| 2026-07-16 | Lawrence Bryan Jay | A-Award | 20,000 | $89K |
| 2026-07-16 | Brams Matthew | A-Award | 53,600 | $237K |
| 2026-07-16 | Brams Matthew | A-Award | 26,400 | $117K |
| 2026-07-16 | Hargroves Thomas Jeffrey | A-Award | 20,000 | $89K |
| 2026-07-16 | Callahan Jennifer L. | A-Award | 40,200 | $178K |
| 2026-07-16 | Callahan Jennifer L. | A-Award | 19,800 | $88K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $418470 | $1.2M | $16.5M | $5.4M | $52416 | $12.2M | $11.0M |
| Short-term Investments | $18723 | $933 | $933 | 0 | 0 | 0 | 0 |
| Receivables | $113240 | $151772 | 0 | $234432 | $14622 | $26325 | $8013 |
| Inventory | 0 | 0 | 0 | $100339 | 0 | 0 | 0 |
| Total Current Assets | $978317 | $1.8M | $18.9M | $7.9M | $578594 | $12.7M | $12.0M |
| Property, Plant & Equipment | $4.2M | $4.0M | $4.0M | $3.5M | $2.9M | $2.2M | $3.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $5.3M | $5.8M | $22.9M | $11.4M | $3.5M | $14.9M | $15.1M |
| Accounts Payable | $1.9M | $975114 | $264687 | $762357 | $5.2M | $1.3M | $2.0M |
| Short-term Debt | 0 | $500335 | 0 | $5.0M | $3.0M | $2.5M | $6.3M |
| Total Current Liabilities | $3.0M | $3.4M | $1.2M | $7.0M | $10.2M | $5.0M | $10.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $2.4M | $1.2M |
| Total Liabilities | $4.7M | $4.5M | $2.0M | $7.5M | $10.4M | $7.4M | $12.6M |
| Retained Earnings | 0 | -$31.0M | -$51.7M | -$69.4M | -$92.9M | -$108.5M | -$132.4M |
| Total Equity | $615880 | $1.3M | $20.8M | $3.9M | -$6.9M | $7.5M | $2.5M |
| Total Debt | $2.1M | $2.0M | $1.2M | $5.9M | $3.5M | $5.1M | $8.8M |
| Net Debt | $1.7M | $848060 | -$15.3M | $509767 | $3.5M | -$7.1M | -$2.2M |
| Working Capital | -$2.0M | -$1.6M | $17.7M | $856852 | -$9.6M | $7.7M | $1.7M |
Financial Health
| Debt / Equity | 0.27 |
| Current Ratio | 3.50 |
Profitability
| Return on Equity | -894.81% |
| Return on Invested Capital | -176.51% |
| Return on Assets | -148.94% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLR · BCTX · CASI · CLSD · ENTO · KAPA · LEXX
Explore sector: Healthcare · Biotechnology
More sections of CING: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks